NEW YORK (GenomeWeb News) – Genelex and Mental Health Connections announced today that have merged their firms, creating a new company focused on personalized prescribing services.
The merger combines Seattle-based Genelex's DNA Drug Sensitivity testing products, which have been designed to help physicians predict response to certain over-the-counter and prescription drugs, with MHC's GeneMedRx drug and gene interaction software. Genelex also offers paternity testing services and ancestry DNA testing.
Financial terms of the agreement were not disclosed.
The firms will operate under the Genelex name, with Genelex CEO Howard Coleman maintaining that title for the combined entity. Robert Patterson, principal of Lexington, Mass.-based MHC, will serve as chief informatics officer.
Coleman said in a statement that the combination of the firms' technologies "is a major advance in our ability to solve the epidemic of medication-driven adverse drug reactions, interactions, and treatment failures."